CRISPR Therapeutics AG [CRSP] is 7.63% higher this YTD. Is it still time to buy?

- Advertisements -

CRISPR Therapeutics AG [NASDAQ: CRSP] gained 11.32% on the last trading session, reaching $43.75 price per share at the time. The company report on October 31, 2023 at 5:53 PM that CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease.

-Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease (SCD)-.

- Advertisements -

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


CRISPR Therapeutics AG represents 78.51 million in outstanding shares, while the company has a total market value of $3.47 billion with the latest information. CRSP stock price has been found in the range of $38.93 to $38.93.

If compared to the average trading volume of 1.09M shares, CRSP reached a trading volume of 4702890 in the most recent trading day, which is why market watchdogs consider the stock to be active.

- Advertisements -

Here is what top equities market gurus are saying about CRISPR Therapeutics AG [CRSP]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRSP shares is $86.96 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRSP stock is a recommendation set at 2.03. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for CRISPR Therapeutics AG shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 17, 2023.

The Average True Range (ATR) for CRISPR Therapeutics AG is set at 2.34, with the Price to Sales ratio for CRSP stock in the period of the last 12 months amounting to 20.42. The Price to Book ratio for the last quarter was 1.91, with the Price to Cash per share for the same quarter was set at 22.27.

- Advertisements -

Trading performance analysis for CRSP stock

CRISPR Therapeutics AG [CRSP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.66. With this latest performance, CRSP shares gained by 1.89% in over the last four-week period, additionally sinking by -11.06% over the last 6 months – not to mention a drop of -16.41% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRSP stock in for the last two-week period is set at 53.99, with the RSI for the last a single of trading hit 59.70, and the three-weeks RSI is set at 49.46 for CRISPR Therapeutics AG [CRSP]. The present Moving Average for the last 50 days of trading for this stock 45.74, while it was recorded at 39.94 for the last single week of trading, and 51.40 for the last 200 days.

CRISPR Therapeutics AG [CRSP]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and CRISPR Therapeutics AG [CRSP] shares currently have an operating margin of -56190.40 and a Gross Margin at -11120.53. CRISPR Therapeutics AG’s Net Margin is presently recorded at -54271.70.

Return on Total Capital for CRSP is now -28.38, given the latest momentum, and Return on Invested Capital for the company is -27.57. Return on Equity for this stock declined to -30.42, with Return on Assets sitting at -26.03. When it comes to the capital structure of this company, CRISPR Therapeutics AG [CRSP] has a Total Debt to Total Equity ratio set at 13.01. Additionally, CRSP Total Debt to Total Capital is recorded at 11.51, with Total Debt to Total Assets ending up at 10.88. Long-Term Debt to Equity for the company is recorded at 12.17, with the Long-Term Debt to Total Capital now at 10.77.

Reflecting on the efficiency of the workforce at the company, CRISPR Therapeutics AG [CRSP] managed to generate an average of -$1,419,596 per employee. Receivables Turnover for the company is 0.12 with a Total Asset Turnover recorded at a value of 0.00.CRISPR Therapeutics AG’s liquidity data is similarly interesting compelling, with a Quick Ratio of 14.00 and a Current Ratio set at 14.00.

An analysis of Institutional ownership at CRISPR Therapeutics AG [CRSP]

The top three institutional holders of CRSP stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in CRSP stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in CRSP stock with ownership which is approximately 5.7994%.

- Advertisements -

Leave a Reply

Your email address will not be published. Required fields are marked *